Table 3.
Hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between ILTCs, RFS, and endometrial cancer-specific survival by stage, N=295
| ILTCs | RFS1 | ILTCs | EC-specific survival | ||||
|---|---|---|---|---|---|---|---|
| recurrences, n (%)2 | HR (95% CI)3 | HR (95% CI)4 | deaths, n (%)2 | HR (95% CI)3 | HR (95% CI)4 | ||
| Stage I, n=183 | |||||||
| Absent (n=173) | 16 (9.3) | 1.00 | 1.00 | Absent (n=175) | 10 (5.7) | 1.00 | 1.00 |
| Present (n=8) | 2 (25.0) | 3.47 (0.79, 15.34) | 4.07 (0.85, 19.40) | Present (n=8) | 2 (25.0) | 4.79 (1.05, 21.90) | 4.19 (0.84, 20.78) |
| Stage II, n=23 | |||||||
| Absent (n=20) | 10 (50.0) | 1.00 | 1.00 | Absent (n=19) | 5 (26.3) | 1.00 | 1.00 |
| Present (n=3) | 0 (0.0) | --- | --- | Present (n=3) | 0 (0.0) | --- | --- |
| Stage III, n=59 | |||||||
| Absent (n=45) | 29 (64.4) | 1.00 | 1.00 | Absent (n=47) | 27 (57.5) | 1.00 | 1.00 |
| Present (n=12) | 4 (33.3) | 0.36 (0.13, 1.03) | 0.39 (0.12, 1.29) | Present (n=12) | 5 (41.7) | 0.56 (0.21, 1.46) | 0.75 (0.24, 2.29) |
| Stage IV, n=30 | |||||||
| --- | --- | --- | --- | Absent (n=17) | 9 (52.9) | 1.00 | 1.00 |
| --- | --- | --- | --- | Present (n=11) | 8 (72.7) | 1.71 (0.65, 4.50) | 3.33 (0.71, 15.59) |
1
Women with stage IV disease excluded from model
2
row percentage
3
Unadjusted HRs and 95% CI
4
HRs and 95% CIs adjusted for age (<55, 55–64, ≥65) and histology (low-grade endometrioid, high-grade endometrioid, serous, mixed epithelial, carcinosarcoma, clear cell)